E J Smolders1,2, C Smit3, Ctmm de Kanter4, Asm Dofferhoff5, J E Arends6, K Brinkman7, B Rijnders8, M van der Valk9, P Reiss3,9,10, D M Burger1,2. 1. Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 3. HIV Monitoring Foundation, Amsterdam, The Netherlands. 4. Department of Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Internal Disease and Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Internal Medicine and Infectious Diseases, University Medical Center, Utrecht, The Netherlands. 7. Department of Internal Medicine and Infectious Diseases, OLVG, Amsterdam, The Netherlands. 8. Department of Internal Medicine and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 9. Division of Infectious Diseases, Academic Medical Center, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands. 10. Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Abstract
OBJECTIVES: Direct-acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection can cause drug-drug interactions (DDIs) with combination antiretroviral therapy (cART) and non-cART co-medication. We mapped how physicians manage DDIs between DAAs and co-medication and analysed treatment outcomes. METHODS: Data were prospectively collected as part of the ATHENA HIV observational cohort and retrospectively analysed. Dutch patients with HIV/HCV coinfection who initiated treatment with DAAs between January 2015 and May 2016 were included. Co-medication 3 months prior to and during DAA therapy was identified. Potential DDIs with the DAAs were checked using http://hep-druginteractions.org. DDIs were categorized as: (1) no interaction expected; (2) potential interaction; (3) contra-indication; (4) no recommendation. These categories were used to determine which patients switched or had a DDI during DAA therapy with co-medication. RESULTS: A total of 423 patients were treated with DAAs, of whom 418 (99%) used cART and 251 (59%) used non-cART co-medication. Before commencing DAA treatment, in 17 of 84 (20%) patients the non-cART co-medication which could result in a category 2/3 DDI was discontinued before DAA initiation, including two of six (33%) prescriptions of category 3 drugs. A total of 196 of 418 (47%) patients had a category 2/3 DDI between their DAA regimen and cART. Category 2/3 DDIs were prevented by switching cART in 78 of 147 (53%) and 47 of 49 (98%) patients. Overall, 367 of 423 (87%) patients have achieved a sustained virological response (33 in follow-up). CONCLUSIONS: Prescription patterns suggest that physicians are aware of potential DDIs between co-medication and DAAs, in particular potential DDIs with cART. Greater awareness is needed concerning category 3 interactions between non-cART co-medication and DAAs.
OBJECTIVES: Direct-acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection can cause drug-drug interactions (DDIs) with combination antiretroviral therapy (cART) and non-cART co-medication. We mapped how physicians manage DDIs between DAAs and co-medication and analysed treatment outcomes. METHODS: Data were prospectively collected as part of the ATHENA HIV observational cohort and retrospectively analysed. Dutch patients with HIV/HCV coinfection who initiated treatment with DAAs between January 2015 and May 2016 were included. Co-medication 3 months prior to and during DAA therapy was identified. Potential DDIs with the DAAs were checked using http://hep-druginteractions.org. DDIs were categorized as: (1) no interaction expected; (2) potential interaction; (3) contra-indication; (4) no recommendation. These categories were used to determine which patients switched or had a DDI during DAA therapy with co-medication. RESULTS: A total of 423 patients were treated with DAAs, of whom 418 (99%) used cART and 251 (59%) used non-cART co-medication. Before commencing DAA treatment, in 17 of 84 (20%) patients the non-cART co-medication which could result in a category 2/3 DDI was discontinued before DAA initiation, including two of six (33%) prescriptions of category 3 drugs. A total of 196 of 418 (47%) patients had a category 2/3 DDI between their DAA regimen and cART. Category 2/3 DDIs were prevented by switching cART in 78 of 147 (53%) and 47 of 49 (98%) patients. Overall, 367 of 423 (87%) patients have achieved a sustained virological response (33 in follow-up). CONCLUSIONS: Prescription patterns suggest that physicians are aware of potential DDIs between co-medication and DAAs, in particular potential DDIs with cART. Greater awareness is needed concerning category 3 interactions between non-cART co-medication and DAAs.
Authors: Fiona Marra; Christoph Höner Zu Siederdissen; Saye Khoo; David Back; Michael Schlag; Sivi Ouwerkerk-Mahadevan; Ceyhun Bicer; Isabelle Lonjon-Domanec; Wolfgang Jessner; Maria Beumont-Mauviel; Ronald Kalmeijer; Markus Cornberg Journal: Br J Clin Pharmacol Date: 2018-02-21 Impact factor: 4.335
Authors: A Maughan; K Sadigh; V Angulo-Diaz; C Mandimika; M Villanueva; J K Lim; O Ogbuagu Journal: BMC Infect Dis Date: 2019-05-03 Impact factor: 3.090
Authors: Andrea Giacomelli; Alice Ranzani; Letizia Oreni; Elena Gervasi; Angelica Lupo; Anna Lisa Ridolfo; Massimo Galli; Stefano Rusconi Journal: Drug Des Devel Ther Date: 2019-07-09 Impact factor: 4.162
Authors: Soraia M Machado; Aline G Vigani; Andrea G Leite; Ana Claudia M Diaz; Paulo Roberto A Ferreira; Dimas Carnaúba-Júnior; Simone B Tenore; Carlos Eduardo Brandão-Mello; Mario P Gonzalez; Fabiana Siroma; Kleber D Prado; Delzi V Nunes; Gaspar Lisboa-Neto; João Renato R Pinho; Fernanda M Malta; Raymundo S Azevedo; Steven S Witkin; Maria Cássia Mendes-Correa Journal: Medicine (Baltimore) Date: 2020-07-24 Impact factor: 1.817